🟩 Nilonix 150 mg
Generic Name: Nilotinib
Brand Name: Nilonix
Manufacturer: Beacon Pharmaceuticals Ltd.
Dosage Form & Strength: Capsule, 150 mg
Therapeutic Class: Tyrosine Kinase Inhibitor (TKI) | Anticancer Agent
📌 Indications:
Nilonix (Nilotinib) is indicated for the treatment of:
-
Philadelphia chromosome–positive Chronic Myeloid Leukemia (Ph+ CML) in the chronic phase and accelerated phase, both in newly diagnosed adults and in those resistant or intolerant to prior therapy, including imatinib.
💊 Pharmacology:
Nilotinib is a selective BCR-ABL tyrosine kinase inhibitor that blocks the ATP-binding site of the BCR-ABL oncoprotein, which is the abnormal tyrosine kinase responsible for uncontrolled leukemic cell proliferation in CML.
-
More potent than imatinib in inhibiting BCR-ABL.
-
Also inhibits other kinases such as PDGFR and KIT.
-
Reduces leukemic cell proliferation and induces apoptosis.
💉 Dosage & Administration:
-
Recommended dose: 300 mg twice daily (two 150 mg capsules) taken approximately 12 hours apart.
-
Take on an empty stomach — at least 2 hours after a meal and avoid food for at least 1 hour after taking the dose.
-
Swallow capsules whole with water.
-
Dose adjustments may be required in case of side effects or certain co-morbidities.
⚠️ Precautions & Warnings:
-
QT prolongation risk — ECG monitoring before and during therapy.
-
Monitor electrolytes (potassium, magnesium) regularly.
-
May cause myelosuppression — regular blood counts needed.
-
Use caution in patients with hepatic impairment.
-
Avoid strong CYP3A4 inhibitors or inducers.
❌ Contraindications:
🤰 Pregnancy & Lactation:
⚕️ Side Effects:
Common:
-
Rash, itching
-
Nausea, vomiting
-
Fatigue, headache
-
Constipation or diarrhea
-
Myalgia, arthralgia
Serious:
🧊 Storage Conditions:
-
Store below 30°C, in a cool, dry place.
-
Protect from light and moisture.
-
Keep out of reach of children.